Compare Enveric Biosciences Inc (ENVB) vs Essex Property Trust, Inc. (ESS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Essex Property Trust, Inc. — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Essex Property Trust, Inc. trades at $282.11 (market cap $18.20B). The key difference: Essex Property Trust, Inc. is far larger — about 2935.5× Enveric Biosciences Inc's market cap, and Essex Property Trust, Inc. pays a 3.66% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | ESS | |
|---|---|---|
Market Cap | $6.20M | $18.20B |
Sector | Health | Real Estate |
52-Week High | $17.40 | $298.33 |
52-Week Low | $1.27 | $239.61 |
Enterprise Value | $1.30M | $24.80B |
Dividend Yield | — | 3.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
ESS trades at $288.1, up 1.05% daily, with a neutral technical signal and support near $284. The stock shows strong profitability with a 21.48% net margin and recent Q2 2026 earnings miss on EPS but beat on FFO, leading to raised full-year guidance. Revenue growth is steady, reaching $1.89B in 2025, though net income declined to $670M from $742M in 2024.
Outlook is cautiously optimistic with a consensus price target of $305.86, implying ~6% upside. Risks include high debt levels (debt-to-asset ratio of 51.92% in 2024) and regional economic exposure. Analyst sentiment is mixed with 40% buy ratings, but institutional interest grew with Amundi increasing its stake in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →
